BRIDGEWATER, N.J., January 23, 2025--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved memantine ...
Amneal Pharmaceuticals (AMRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Try Now>> See the top stocks recommended by analysts >> Read More on AMRX: Amneal Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback